Table 3.

Cox regression models of recurrence and cancer-specific death after neoadjuvant chemotherapy and radical cystectomy, adjusted for age, gender, clinical stage (T3/4 vs. T2), age-adjusted Charlson score (0–2, 3–4, 5+), and smoking characteristics included individually

	Recurrence		Cancer-specific death
	HR (95 % CI)	p value	HR (95 % CI)	p value
Smoking status
Age (per 10 years)	1.04 (0.74, 1.47)	0.8	0.91 (0.60, 1.39)	0.7
Male	1.37 (0.74, 2.51)	0.3	2.15 (0.96, 4.85)	0.064
Clinical stage (T3/4 vs. T2)	2.15 (1.25, 3.69)	0.006	3.41 (1.68, 6.90)	0.001
Charlson score		0.6		0.8
0–2	Ref.	-	Ref.	-
3–5	0.73 (0.36, 1.48)	-	0.93 (0.37, 2.29)	-
5+	0.55 (0.12, 2.56)	-	0.47 (0.06, 4.02)	-
Smoking status		0.6		0.9
Never	Ref.	-	Ref.	-
Former	1.24 (0.66, 2.31)	-	0.90 (0.40, 2.03)	-
Active	0.91 (0.44, 1.84)	-	1.07 (0.44, 2.60)	-
Packs per day
Age (per 10 years)	1.08 (0.76, 1.54)	0.7	0.91 (0.60, 1.38)	0.7
Male	1.40 (0.76, 2.59)	0.3	2.00 (0.90, 4.46)	0.089
Clinical stage (T3/4 vs. T2)	2.17 (1.25, 3.76)	0.006	3.21 (1.59, 6.49)	0.001
Charlson score		0.5		0.8
0–2	Ref.	-	Ref.	-
3–5	0.69 (0.34, 1.41)	-	0.86 (0.35, 2.09)	-
5+	0.54 (0.12, 2.52)	-	0.49 (0.06, 4.15)	-
Packs per day	1.25 (0.95, 1.63)	0.11	1.17 (0.81, 1.70)	0.4
Pack-years
Age (per 10 years)	1.07 (0.75, 1.52)	0.7	0.90 (0.59, 1.37)	0.6
Male	1.44 (0.78, 2.67)	0.2	2.05 (0.92, 4.58)	0.081
Clinical stage (T3/4 vs. T2)	2.18 (1.26, 3.78)	0.006	3.25 (1.60, 6.60)	0.001
Charlson score		0.5		0.8
0–2	Ref.	-	Ref.	-
3–5	0.71 (0.35, 1.44)	-	0.86 (0.36, 2.10)	-
5+	0.52 (0.11, 2.43)	-	0.46 (0.06, 3.90)	-
Pack-years (per 10 years)	1.05 (0.97, 1.14)	0.2	1.05 (0.94, 1.17)	0.4

HR hazard ratio, CI confidence interval